Immunotherapy response boosted by tumor-penetrating peptides in mice

Written by Louis Gautier, Future Science Group

Recent research has shown that oligonucleotides delivered to tumor sites via targeted nanoparticles can markedly improve response rates to immunotherapy in cancer treatment. The studies in mice found that the dual therapy halted tumor growth and could stop the growth of tumors elsewhere in the body. The Massachusetts Institute of Technology (MIT; MA, USA) research team recently published the results of their study in PNAS. They describe how a greater response to immunotherapy can be achieved by delivering immune-stimulatory oligonucleotides to tumor sites via tumor-penetrating peptide-bound nanoparticles. The investigation was designed to make immunotherapy and immune-checkpoint inhibition a viable therapy...

To view this content, please register now for access

It's completely free